AXXESS / aegis therapies®

THE IMPORTANCE OF THERAPY IN THE PDGM MODEL

PRESENTERS

Wendy Conlon MSPT
Vice President of Client Services
Axxess

Dawn Greaves PT, DPT
Vice President of Home Services
At Home with Aegis

The Future…

At Axxess we believe the future of healthcare is in the home. We empower and improve the delivery of quality healthcare services at home through our industry thought leadership and innovative technology solutions.

Learning Objectives

- PDGM and Therapy
- Value-Based Therapy
- PDGM Therapy Expertise
- Determining Functional Status
- A Successful PDGM Transition

What We Know…

- The majority of healthcare dollars are utilized in the last 18 months of life. *Source: CMS, 2018*
- ¼ of traditional Medicare spending is for services in the last year of life. *Source: Kaiser Family Foundation, 2015*
- Healthcare in the home affords quality medical care in a cost-effective model.

Evidence-Based Therapy Care

A study, led by University of Rochester School of Nursing assistant professor Jinjiao Wang Ph.D., RN, found that an average of one to two home health physical therapy sessions a week can help lower the risk of rehospitalization by 82% in the target population.

PDGM

- Patient-Driven Groupings Model
- Bipartisan Budget Act of 2018
- Developed to improve reimbursement for all types of patients eligible for home health benefits
- Therapy thresholds have been eliminated
- Reimbursement closely aligned according to patient clinical characteristics and need

Our Patients Under PDGM

The physiology of the geriatric patient does not change January 1, 2020.

- Admission Source: Institutional vs. Community
- Clinical Grouping
- Functional Status
- Comorbidity

Clinical Groups	Percent of 30-Day Periods
Behavioral Health	3.4%
Complex Nursing Interventions	3.6%
Musculoskeletal Rehabilitation	18.4%
Neuro Rehabilitation	10.4%
Wound	9.0%
MMTA - Surgical Aftercare	3.3%
MMTA - Cardiac and Circulatory	17.5%
MMTA - Endocrine	4.7%
MMTA - Gastrointestinal tract and Genitourinary system	4.4%
MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases	3.8%
MMTA - Respiratory	8.0%
MMTA - Other	13.5%

CMS Percentage of 30-Day Periods by Clinical Group

Goal of Home Healthcare

- Improve Patient Outcome
  - Improve Function
  - Reduce Fall and Injury
  - Manage Medication
- Reduce Hospital Readmission
- Stellar Patient Satisfaction

Key Elements for Therapy

- Detailed referral
- Accurate coding
- Thorough functional assessment
- Thoughtful evidence-based care planning
- Utilization of PTAs and COTAs
- Maximizing every skilled encounter
- Ongoing interdisciplinary assessment and discussion
- Focused goal-oriented care provided efficiently

Therapy Expertise

- Know your baseline - Understanding the impact variables
  - Questionable encounters and therapy
  - Questionable encounters and admission source
  - Impact of functional impairment scores
- Therapy's role in:
  - Primary diagnosis support
  - Condition management
  - Focus on function
  - Outcomes



Therapy Utilization and Questionable Encounters



Data presented at the NAHC PDGM Summit February 5th, New Orleans, LA – Source LDS 2017 data file

Community Admissions and Questionable Encounters



Data source: ABILITY Network, national client database, 2017 episodes

"Early" = SOC
"Later" = Recert or ROC

Data presented at the NAHC PDGM Summit February 5th, New Orleans, LA – Source LDS 2017 data file

Functional Impairment Summary Table

Variable	Response Category	Response	Points
M1800 Grooming	1	2.3	4
M1810 Upper Body Dressing	1	2.3	6
M1820 Lower Body Dressing	1	2	5
	2	3	11
M1830 Bathing	1	2	3
	2	3.4	13
	3	5,6	21
M1840 Toilet Transfer	1	2,3,4	4
M1850 Transferring	1	1	4
	2	2,3,4,5	8
M1860 Ambulation/Locomotion	1	2	10
	2	3	12
	3	4,5,6	24
M1033 Risk of Rehospitalization	4 or > items checked	From 1 - 7	11

PDGM Functional Score Impact

Complex Nursing Example:

- Institutional, Early, **Low** Functional Impairment, Low Comorbidity = 1.1936
- Institutional, Early, **Medium** Functional Impairment, Low Comorbidity = 1.4004
    - Difference of 17%

MMTA Endocrine Example:

- Community, Late, **Low** Functional Impairment, High Comorbidity = .8718
- Community, Late, **Medium** Functional Impairment, High Comorbidity = 1.0367
    - Difference of 19%

MMTA Cardio Example:

- Community, Early, **Low** Functional Impairment, High Comorbidity =1.1569
- Community, Early, **Medium** Functional Impairment, High Comorbidity = 1.3103
    - Difference of 13%

PDGM Analysis

PDGM Case Mix Weights Analysis by Clinical Group

Higher Weights → Lower Weights

	Average	1.3980	1.3697	1.2785	1.2444	1.1657	1.1493	1.1391	1.1280	1.1180	1.1087	1.0900	1.0807
	Max	1.8586	1.8228	1.7449	1.7123	1.6261	1.6069	1.5633	1.5773	1.5687	1.5558	1.5381	1.5695
	Median	**1.4398**	**1.4152**	**1.3173**	**1.2824**	**1.2075**	**1.1925**	**1.1951**	**1.1754**	**1.1646**	**1.1572**	**1.1379**	**1.1083**
	Min	0.8158	0.7821	0.6871	0.6710	0.5898	0.5681	0.5479	0.5601	0.5450	0.5277	0.5015	0.4784

Source	Timing	Level	Comorb	Wound	Neuro	MMTA - Endocrine	MS Rehab	MMTA - Other	MMTA - Cardiac	Complex	MMTA - Infectious	MMTA - Respiratory	MMTA - GI/GU	Behavioral Health	MMTA - Surgical Aftercare
Institutional	Early	High	2	1.8586	1.8228	1.7449	1.7123	1.6261	1.6069	1.5633	1.5773	1.5687	1.5558	1.5381	1.5695
Institutional	Early	High	1	1.7335	1.6978	1.6199	1.5872	1.5011	1.4818	1.4382	1.4523	1.4436	1.4307	1.4131	1.4444
Institutional	Early	High	0	1.6739	1.6381	1.5603	1.5276	1.4415	1.4222	1.3786	1.3927	1.3840	1.3711	1.3535	1.3848
Institutional	Early	Medium	2	1.7391	1.7237	1.6228	1.5692	1.5006	1.4923	1.5255	1.4660	1.4596	1.4620	1.4498	1.4136
Institutional	Early	Medium	1	1.6140	1.5987	1.4977	1.4441	1.3755	1.3672	1.4004	1.3410	1.3346	1.3370	1.3247	1.2886
Institutional	Early	Medium	0	1.5544	1.5391	1.4381	1.3845	1.3159	1.3076	1.3408	1.2814	1.2750	1.2773	1.2651	1.2289
Institutional	Early	Low	2	1.5865	1.5528	1.4579	1.4418	1.3606	1.3389	1.3187	1.3309	1.3157	1.2985	1.2722	1.2492
Institutional	Early	Low	1	1.4615	1.4278	1.3329	1.3167	1.2355	1.2138	1.1936	1.2058	1.1907	1.1734	1.1472	1.1241
Institutional	Early	Low	0	1.4019	1.3681	1.2732	1.2571	1.1759	1.1542	1.1340	1.1462	1.1311	1.1138	1.0875	1.0645
Institutional	Late	High	2	1.7194	1.6836	1.6058	1.5731	1.4870	1.4677	1.4241	1.4382	1.4295	1.4166	1.3990	1.4303
Institutional	Late	High	1	1.5944	1.5586	1.4807	1.4481	1.3619	1.3427	1.2991	1.3131	1.3045	1.2916	1.2739	1.3053
Institutional	Late	High	0	1.5347	1.4990	1.4211	1.3884	1.3023	1.2831	1.2395	1.2535	1.2449	1.2319	1.2143	1.2457
Institutional	Late	Medium	2	1.5999	1.5846	1.4836	1.4300	1.3614	1.3531	1.3863	1.3269	1.3205	1.3228	1.3106	1.2744
Institutional	Late	Medium	1	1.4749	1.4595	1.3586	1.3050	1.2364	1.2281	1.2613	1.2018	1.1954	1.1978	1.1856	1.1494
Institutional	Late	Medium	0	1.4152	1.3999	1.2989	1.2453	1.1767	1.1684	1.2016	1.1422	1.1358	1.1382	1.1260	1.0898
Institutional	Late	Low	2	1.4474	1.4136	1.3187	1.3026	1.2214	1.1997	1.1795	1.1917	1.1766	1.1593	1.1330	1.1100
Institutional	Late	Low	1	1.3223	1.2886	1.1937	1.1776	1.0964	1.0747	1.0545	1.0667	1.0515	1.0342	1.0080	0.9850
Institutional	Late	Low	0	1.2627	1.2290	1.1341	1.1179	1.0367	1.0150	0.9948	1.0070	0.9919	0.9746	0.9484	0.9254
Community	Early	High	2	1.6766	1.6408	1.5630	1.5303	1.4442	1.4249	1.3813	1.3954	1.3867	1.3738	1.3562	1.3875
Community	Early	High	1	1.5516	1.5158	1.4379	1.4053	1.3191	1.2999	1.2563	1.2703	1.2617	1.2487	1.2311	1.2625
Community	Early	High	0	1.4919	1.4562	1.3783	1.3456	1.2595	1.2403	1.1966	1.2107	1.2021	1.1891	1.1715	1.2029
Community	Early	Medium	2	1.5571	1.5418	1.4408	1.3872	1.3186	1.3103	1.3435	1.2841	1.2777	1.2800	1.2678	1.2316
Community	Early	Medium	1	1.4321	1.4167	1.3158	1.2622	1.1936	1.1853	1.2185	1.1590	1.1526	1.1550	1.1428	1.1066
Community	Early	Medium	0	1.3724	1.3571	1.2561	1.2025	1.1339	1.1256	1.1588	1.0994	1.0930	1.0954	1.0832	1.0470
Community	Early	Low	2	1.4046	1.3708	1.2759	1.2598	1.1786	1.1569	1.1367	1.1489	1.1338	1.1165	1.0902	1.0672
Community	Early	Low	1	1.2795	1.2458	1.1509	1.1348	1.0536	1.0319	1.0117	1.0239	1.0087	0.9914	0.9652	0.9422
Community	Early	Low	0	1.2199	1.1862	1.0913	1.0751	0.9939	0.9722	0.9520	0.9642	0.9491	0.9318	0.9056	0.8826
Community	Late	High	2	1.2725	1.2367	1.1588	1.1262	1.0401	1.0208	0.9772	0.9913	0.9826	0.9697	0.9521	0.9834
Community	Late	High	1	1.1475	1.1117	1.0338	1.0012	0.9150	0.8958	0.8522	0.8662	0.8576	0.8446	0.8270	0.8584
Community	Late	High	0	1.0878	1.0520	0.9742	0.9415	0.8554	0.8361	0.7925	0.8066	0.7979	0.7850	0.7674	0.7987
Community	Late	Medium	2	1.1530	1.1377	1.0367	0.9831	0.9145	0.9062	0.9394	0.8799	0.8735	0.8759	0.8637	0.8275
Community	Late	Medium	1	1.0279	1.0126	0.9116	0.8581	0.7894	0.7812	0.8143	0.7549	0.7485	0.7509	0.7387	0.7025
Community	Late	Medium	0	0.9683	0.9530	0.8520	0.7984	0.7298	0.7215	0.7547	0.6953	0.6889	0.6913	0.6790	0.6429
Community	Late	Low	2	1.0005	0.9667	0.8718	0.8557	0.7745	0.7528	0.7326	0.7448	0.7297	0.7124	0.6861	0.6631
Community	Late	Low	1	0.8754	0.8417	0.7468	0.7307	0.6495	0.6277	0.6076	0.6198	0.6046	0.5873	0.5611	0.5381
Community	Late	Low	0	0.8158	0.7821	0.6871	0.6710	0.5898	0.5681	0.5479	0.5601	0.5450	0.5277	0.5015	0.4784
	Variance														

Less Volatile/Vulnerable to Change → More Volatile/Vulnerable to Change

Data Source = CMS Home Health PDGM Case Mix Weights and LUPA Thresholds File

https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HomeHealthPPS/HH-PDGM.html

Value-Based Therapy Outcomes



Source 1 = Home Health Compare Database (Home Health Care Agencies - Jan, 2019) https://data.medicare.gov/Home-Health-Compare/Home-Health-Care-Agencies/6jpm-sxkc
Source 2 = CMS PDGM Agency Level Impact Analysis https://www.cms.gov/center/provider-type/home-health-agency-hha-center.html

Delivering on Therapy Quality



Summary

- Coding
  - Avoid questionable encounter codes
  - Appropriate Comorbidity codes
- 30-Day Periods
  - Develop patient outcome-driven clinical pathways to optimize visit utilization and patient outcomes
- 60-Day Periods
  - Consider care plans that extend into the second 30-day period to optimize patient outcomes
- LUPA
  - Utilize the Axxess PDGM Impact Tool to know the LUPA threshold for the 432 HHRGs in PDGM
- Functional Impairment Group and Clinical Groupings
  - Develop therapy patient outcome-driven pathways according to Functional Impairment Group for most appropriate therapy utilization and optimal patient outcome under the Clinical Group

Considerations for Therapy

Evaluate, know, and understand therapy utilization and practice patterns, including patient outcomes for your agency, then ensure:

- Completion of thorough Therapy Assessment
  - Standardized and Validated Tests: Tinetti, TUG, BORG, CLOX Test, FIM, Barthel Index, etc.
  - Establish functional baseline directly correlated to primary diagnosis
- Disease management focused care
- Engage PTA and COTA as appropriate
- Implement robust home exercise program and solicit caregiver engagement
- Explore telehealth program that allows for interactive video monitoring and engagement

PDGM Therapy Expertise

- Work Smarter
- Communication
- Thorough Assessment
- Knowledge of OASIS
- Engage Therapists
- Care Coordination

Determining Functional Status

- Observation of patient completing the 8 functional task items
- Interview patient and caregiver to understand common movement patterns
- Interdisciplinary collaboration
- Identify and consider patient safety when scoring OASIS items

Successful PDGM Transition

- Knowledge of OASIS-D to ensure accuracy in scoring
- Thorough assessment
- Create strong interdisciplinary communication
- Develop Unified Plan of Care addressing specific patient need
- Optimize resources
- Keep focused on value over volume
- Avoid radical change without detailed analysis of therapy practice and patient outcome

The Value of Therapy

The skilled eye of a therapist to accurately define patient deficiencies is the foundation of a successful functional outcome.

Additional Resources

Aegis Therapies PDGM Resources

https://aegistherapies.com/categories/pdgm/

Axxess PDGM Resources

http://www.axxess.com/pdgm

Axxess PDGM Seminars

Dallas, TX – September 24

Houston, TX - September 26

Las Vegas, NV – October 4

Chicago, IL – October 22

Boston, MA – November 5

Columbus, OH – November 12

Fort Lauderdale, FL – November 14

McAllen, TX – December 3

San Antonio, TX – December 5

Register at: axxess.com/PDGM/seminars

THANK YOU!

Slides and a recording of this webinar will be available at axxess.com/pdgm